Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-arm phase 3 study of trastuzumab emtansine in previously treated HER2-positive advanced or metastatic breast cancer
NL-OMON39697Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Feb 2013
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of trastuzumab emtansine in breast cancer, sponsored by Roche. Primary endpoints: Incidence, nature, and severity of adverse events and serious adverse events, Incidence of congestive heart failure and 4 more. Started Feb 2013; status: active, not recruiting.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON39697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39697.